• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

液体活检：探寻前列腺癌耐药的线索。

Liquid biopsy: Clues on prostate cancer drug resistance.

机构信息

Division of Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

出版信息

Sci Transl Med. 2015 Nov 4;7(312):312fs45. doi: 10.1126/scitranslmed.aad4008.

DOI:10.1126/scitranslmed.aad4008
PMID:26537254
Abstract

Analysis of tumor-derived cell-free DNA in blood yields insights into drug resistance in patients with castration-resistant prostate cancer (Romanel et al., this issue).

摘要

对血液中肿瘤游离 DNA 的分析为去势抵抗性前列腺癌患者的耐药性提供了深入了解（Romanel 等人，本期）。

相似文献

1
Liquid biopsy: Clues on prostate cancer drug resistance.液体活检：探寻前列腺癌耐药的线索。
Sci Transl Med. 2015 Nov 4;7(312):312fs45. doi: 10.1126/scitranslmed.aad4008.
2
An original patient-derived xenograft of prostate cancer with cyst formation.一个伴有囊肿形成的原发性前列腺癌患者来源异种移植瘤。
Prostate. 2016 Aug;76(11):994-1003. doi: 10.1002/pros.23188. Epub 2016 Apr 21.
3
[Sequential therapy for castration-resistant prostate cancer].[去势抵抗性前列腺癌的序贯治疗]
Nihon Rinsho. 2016 May 20;74 Suppl 3:644-8.
4
Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?醋酸阿比特龙停药后的代谢及前列腺特异性抗原反应：去势抵抗性前列腺癌的一种新临床情况？
Clin Genitourin Cancer. 2013 Dec;11(4):e10-4. doi: 10.1016/j.clgc.2013.04.021. Epub 2013 Jun 27.
5
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.CH5137291是一种雄激素受体核易位抑制化合物，可抑制去势抵抗性前列腺癌细胞的生长。
Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.
6
[Androgen receptor variants in prostate cancer].[前列腺癌中的雄激素受体变体]
Med Sci (Paris). 2017 Aug-Sep;33(8-9):758-764. doi: 10.1051/medsci/20173308021. Epub 2017 Sep 18.
7
Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.回复：罗伯特·J·范·索斯特、埃伦·S·德·莫雷、夏洛特·F·克韦尔丹等。在去势抵抗性前列腺癌中，靶向雄激素受体可导致恩杂鲁胺和多西他赛之间产生体内交叉耐药，但卡巴他赛不会。《欧洲泌尿外科杂志》2015年；67卷：981 - 985页。
Eur Urol. 2016 Mar;69(3):e41-2. doi: 10.1016/j.eururo.2015.07.025. Epub 2015 Jul 26.
8
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.液体活检中雄激素受体的综合分析揭示了去势抵抗性前列腺癌中的新型 AR 结构变异和剪接变异表达模式。
Eur Urol. 2017 Aug;72(2):192-200. doi: 10.1016/j.eururo.2017.01.011. Epub 2017 Jan 16.
9
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.前列腺特异性抗原对延迟联合雄激素阻断治疗的反应预测了去势抵抗性前列腺癌患者后续雌激素和多西他赛治疗后的生存。
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
10
[Castration resistant prostate cancer 2011].[去势抵抗性前列腺癌2011]
Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24.

引用本文的文献

1
Leukocyte Depletion and Size-Based Enrichment of Circulating Tumor Cells Using a Pressure-Sensing Microfiltration Device.使用压力传感微滤装置进行循环肿瘤细胞的白细胞去除和基于大小的富集
ACS Meas Sci Au. 2022 Dec 8;3(2):113-119. doi: 10.1021/acsmeasuresciau.2c00057. eCollection 2023 Apr 19.
2
Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.循环肿瘤细胞作为癌症发病率和复发预测标志物的相关性
Pharmaceuticals (Basel). 2022 Jan 6;15(1):75. doi: 10.3390/ph15010075.
3
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.
在去势抵抗性前列腺癌中，游离DNA检测到的基因改变与恩杂鲁胺和阿比特龙耐药相关。
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.
4
Modern urology perspectives on prostate cancer biomarkers.现代泌尿学对前列腺癌生物标志物的观点。
Cent European J Urol. 2018;71(4):420-426. doi: 10.5173/ceju.2018.1762. Epub 2018 Dec 27.
5
Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation.多参数单细胞分析平台在临床转化中的机遇与挑战。
Clin Transl Sci. 2018 May;11(3):267-276. doi: 10.1111/cts.12536. Epub 2018 Mar 2.
6
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.前列腺癌的预后和预测生物标志物：最新证据及临床意义
Ther Adv Med Oncol. 2017 Aug;9(8):565-573. doi: 10.1177/1758834017719215. Epub 2017 Jul 5.
7
Treatment strategies for DNA repair-deficient prostate cancer.DNA修复缺陷型前列腺癌的治疗策略。
Expert Rev Clin Pharmacol. 2017 Aug;10(8):889-898. doi: 10.1080/17512433.2017.1338138. Epub 2017 Jun 12.
8
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.靶向雄激素受体的N端结构域：一种治疗晚期前列腺癌的新方法。
Oncologist. 2016 Dec;21(12):1427-1435. doi: 10.1634/theoncologist.2016-0161. Epub 2016 Sep 14.
9
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌对新型抗雄激素疗法的耐药性
Clin Med Insights Oncol. 2016 Mar 16;10(Suppl 1):1-9. doi: 10.4137/CMO.S34534. eCollection 2016.
10
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.用于去势抵抗性前列腺癌雄激素轴阻断的新型机制性疗法。
Curr Opin Endocrinol Diabetes Obes. 2016 Jun;23(3):279-90. doi: 10.1097/MED.0000000000000254.